Elizabeth Plimack, MD, MS, FASCO, the Deputy Director of Fox Chase Cancer Center, provides an update on the SWOG S1314 trial for muscle-invasive bladder cancer.

She highlights the four genes that were found to be predictive of pT0 disease after neoadjuvant chemotherapy, and how a biomarker test for these genes may impact patient care and disease management moving forward.